CATX R&D to Revenue
Perspective Therapeutics Inc · R&D to Revenue
CATX R&D to Revenue
Latest reported26597.53%period ending
CATX Quarterly R&D/Revenue (0.00% → 26597.53%)
Latest values, visible window
High-resolution chart · PNG
CATX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 26,597.5309% | |
| 26,639.4737% | |
| 0% | |
| 9,731.5789% | |
| 4,197.931% | |
| 3,078.3198% | |
| 0% | |
| 0% | |
| 2,292.9231% | |
| 1,939.4928% | |
| -116.0527% | |
| 270.7375% | |
| 913.2653% | |
| 210.765% | |
| 33.406% | |
| 41.2347% | |
| 31.7764% | |
| 18.866% | |
| 18.9986% | |
| 27.3791% | |
| 17.2694% | |
| 13.9231% | |
| 12.0814% | |
| 13.0872% | |
| 14.129% | |
| 10.2083% | |
| 12.5567% | |
| 10.0648% | |
| 17.7235% | |
| 15.5405% | |
| 21.7437% | |
| 26.8886% | |
| 35.6831% | |
| 30.0699% | |
| 22.1354% | |
| 29.8927% | |
| 23.0657% | |
| 25.507% | |
| 14.5914% | |
| 15.9112% | |
| 12.7404% | |
| 15.2821% | |
| 4.8978% | |
| 11.4089% | |
| 11.6454% | |
| 12.2095% | |
| 13.1972% | |
| 16.9475% | |
| 20.8708% | |
| 13.5421% | |
| 15.6651% | |
| 14.0002% | |
| 14.5984% | |
| 12.3963% | |
| 15.2929% | |
| 13.394% | |
| 15.8097% | |
| 10.0379% | |
| 15.4365% | |
| 16.5907% | |
| 23.6392% | |
| 13.3315% | |
| 1.2541% | |
| 8.6293% | |
| 8.5392% | |
| 8.225% | |
| 4.3175% | |
| 4.9948% | |
| 10.9648% | |
| 22.0969% | |
| 23.0689% | |
| 14.3822% | |
| 15.4313% | |
| 24.3557% | |
| 22.4953% | |
| 13.8151% | |
| 26.9957% | |
| 26.5628% | |
| 15.2921% | |
| 23.9504% | |
| 29.5398% | |
| 17.9861% | |
| 19.9152% | |
| 12.2239% | |
| 12.2239% | |
| 61.5385% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |